Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 5-6/2013

01.03.2013 | übersicht

Radiofrequenzablation des hepatozellulären Karzinoms

verfasst von: OA Priv.-Doz. Dr. Gerlig Widmann, MD, Peter Schullian, MD, Reto Bale, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2013

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die perkutane Radiofrequenzablation (RFA) hat sich in der Therapie des hepatozellulären Karzinoms etabliert. Aufgrund ihres kurativen Potentials ist sie die Methode der Wahl beim nichtresektablen BCLC (Barcelona Liver Clinic) 0 and A. Die RFA ist eine Alternative zur Resektion beim kleinen HCC und die Methode der Wahl zum Bridging vor Transplantation und bei Rezidiv nach Resektion oder Transplantation. Die technische Machbarkeit der RFA hängt von der Größe und Lokalisation des HCCs und von der Verfügbarkeit der Ablationstechnik (Ein-Nadel Technik, Multi-Nadel Technik) ab. Die stereotaktische Multi-Nadel Technik mit 3D Trajektorien Planung und geführter Nadelplatzierung erweitert dabei substantiell das Spektrum der behandelbaren Läsionen inklusive großvolumiger Tumore. Der Behandlungserfolg ist abhängig von der Realisation von Ablationen mit großem Sicherheitssaum von tumorfreiem Gewebe (A0 Ablation in Analogie zur R0 Resektion), was mithilfe einer Bildfusion von Post- mit Präablationsbildern zu dokumentieren und im Follow-up zu bestätigen ist.
Literatur
1.
Zurück zum Zitat Llovet JM DM, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E, Roskams T, De Baere T, Ducreux M, Mazzaferro V, Bernardi M, Bruix J, Colombo M, Zhu A. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–43. Llovet JM DM, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, Greten TF, Raymond E, Roskams T, De Baere T, Ducreux M, Mazzaferro V, Bernardi M, Bruix J, Colombo M, Zhu A. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908–43.
2.
Zurück zum Zitat Widmann G, Bodner G, Bale R. Tumour ablation: technical aspects. Cancer Imaging. 2009;9(Spec No A):S63–7.CrossRefPubMed Widmann G, Bodner G, Bale R. Tumour ablation: technical aspects. Cancer Imaging. 2009;9(Spec No A):S63–7.CrossRefPubMed
3.
Zurück zum Zitat Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003 Feb;226(2):441–51.CrossRefPubMed Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003 Feb;226(2):441–51.CrossRefPubMed
4.
Zurück zum Zitat Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002 Oct;89(10):1206–22.CrossRefPubMed Mulier S, Mulier P, Ni Y, Miao Y, Dupas B, Marchal G, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002 Oct;89(10):1206–22.CrossRefPubMed
5.
Zurück zum Zitat Widmann G, Schullian P, Haidu M, Bale R. Stereotactic Radiofrequency Ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Interv Radiol. 2012 Jun;35(3):570–80.CrossRef Widmann G, Schullian P, Haidu M, Bale R. Stereotactic Radiofrequency Ablation (SRFA) of liver lesions: technique effectiveness, safety, and interoperator performance. Cardiovasc Interv Radiol. 2012 Jun;35(3):570–80.CrossRef
6.
Zurück zum Zitat Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321–8.CrossRefPubMed Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006 Mar;243(3):321–8.CrossRefPubMed
7.
Zurück zum Zitat Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the „test-of-time approach“. Cancer. 2003 Jun 15;97(12):3027–35.CrossRefPubMed Livraghi T, Solbiati L, Meloni F, Ierace T, Goldberg SN, Gazelle GS. Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the „test-of-time approach“. Cancer. 2003 Jun 15;97(12):3027–35.CrossRefPubMed
8.
Zurück zum Zitat Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000 Mar;18(5):1094–101.PubMed Poon RT, Fan ST, Lo CM, Liu CL, Ng IO, Wong J. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. J Clin Oncol. 2000 Mar;18(5):1094–101.PubMed
9.
Zurück zum Zitat Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000 May;190(5):580–7.CrossRefPubMed Figueras J, Jaurrieta E, Valls C, Ramos E, Serrano T, Rafecas A, et al. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg. 2000 May;190(5):580–7.CrossRefPubMed
10.
Zurück zum Zitat Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003 Sep;238(3):315–21; discussion 21–3.PubMed Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003 Sep;238(3):315–21; discussion 21–3.PubMed
11.
Zurück zum Zitat Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg. 2005 Nov;29(11):1364–73.CrossRefPubMed Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg. 2005 Nov;29(11):1364–73.CrossRefPubMed
12.
Zurück zum Zitat Xu HX, Lu MD, Xie XY, Yin XY, Kuang M, Chen JW, et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol. 2005 Sep;60(9):1018–25.CrossRefPubMed Xu HX, Lu MD, Xie XY, Yin XY, Kuang M, Chen JW, et al. Prognostic factors for long-term outcome after percutaneous thermal ablation for hepatocellular carcinoma: a survival analysis of 137 consecutive patients. Clin Radiol. 2005 Sep;60(9):1018–25.CrossRefPubMed
13.
Zurück zum Zitat Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999 Mar;210(3):655–61.PubMed Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999 Mar;210(3):655–61.PubMed
14.
Zurück zum Zitat Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211–21.CrossRefPubMed Ramsey DE, Kernagis LY, Soulen MC, Geschwind JF. Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S211–21.CrossRefPubMed
15.
Zurück zum Zitat Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009 Dec;72(3):505–16.CrossRefPubMed Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009 Dec;72(3):505–16.CrossRefPubMed
16.
Zurück zum Zitat Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010 Sep;195(3):758–65.CrossRefPubMed Kim YS, Lee WJ, Rhim H, Lim HK, Choi D, Lee JY. The minimal ablative margin of radiofrequency ablation of hepatocellular carcinoma (> 2 and < 5 cm) needed to prevent local tumor progression: 3D quantitative assessment using CT image fusion. AJR Am J Roentgenol. 2010 Sep;195(3):758–65.CrossRefPubMed
17.
Zurück zum Zitat Bale R, Widmann G. Navigated CT-guided interventions. Minim Invasive Ther Allied Technol. 2007;16(4):196–204.CrossRefPubMed Bale R, Widmann G. Navigated CT-guided interventions. Minim Invasive Ther Allied Technol. 2007;16(4):196–204.CrossRefPubMed
18.
Zurück zum Zitat Bale R, Widmann G, Haidu M. Stereotactic radiofrequency ablation. Cardiovasc Interv Radiol. 2010 Aug 24;34(4):852–6.CrossRef Bale R, Widmann G, Haidu M. Stereotactic radiofrequency ablation. Cardiovasc Interv Radiol. 2010 Aug 24;34(4):852–6.CrossRef
19.
Zurück zum Zitat Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol. 2010 Jul;75(1):32–6.CrossRefPubMed Bale R, Widmann G, Stoffner DI. Stereotaxy: breaking the limits of current radiofrequency ablation techniques. Eur J Radiol. 2010 Jul;75(1):32–6.CrossRefPubMed
20.
Zurück zum Zitat Bale R, Widmann G, Schullian P, Haidu M, Pall G, Klaus A, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol. 2012 Apr;22(4):930–7.CrossRefPubMed Bale R, Widmann G, Schullian P, Haidu M, Pall G, Klaus A, et al. Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases. Eur Radiol. 2012 Apr;22(4):930–7.CrossRefPubMed
21.
Zurück zum Zitat Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, et al. Stereotactic Radiofrequency Ablation of Unresectable Intrahepatic Cholangiocarcinomas: a retrospective study. Cardiovasc Interv Radiol. 2011 Oct 18;35(5):1074–82.CrossRef Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H, et al. Stereotactic Radiofrequency Ablation of Unresectable Intrahepatic Cholangiocarcinomas: a retrospective study. Cardiovasc Interv Radiol. 2011 Oct 18;35(5):1074–82.CrossRef
22.
Zurück zum Zitat Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics. 2008 Mar-Apr;28(2):379–90; discussion 90–2.CrossRefPubMed Park MH, Rhim H, Kim YS, Choi D, Lim HK, Lee WJ. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics. 2008 Mar-Apr;28(2):379–90; discussion 90–2.CrossRefPubMed
23.
Zurück zum Zitat Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Interv Radiol. 2010 Feb;33(1):11–7.CrossRef Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Interv Radiol. 2010 Feb;33(1):11–7.CrossRef
24.
Zurück zum Zitat Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008 Jan;12(1):183–91.CrossRefPubMed Ng KK, Poon RT, Lo CM, Yuen J, Tso WK, Fan ST. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg. 2008 Jan;12(1):183–91.CrossRefPubMed
25.
Zurück zum Zitat Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol. 2008;43(1):71–8.CrossRefPubMed Okuwaki Y, Nakazawa T, Shibuya A, Ono K, Hidaka H, Watanabe M, et al. Intrahepatic distant recurrence after radiofrequency ablation for a single small hepatocellular carcinoma: risk factors and patterns. J Gastroenterol. 2008;43(1):71–8.CrossRefPubMed
Metadaten
Titel
Radiofrequenzablation des hepatozellulären Karzinoms
verfasst von
OA Priv.-Doz. Dr. Gerlig Widmann, MD
Peter Schullian, MD
Reto Bale, MD
Publikationsdatum
01.03.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0176-6

Weitere Artikel der Ausgabe 5-6/2013

Wiener Medizinische Wochenschrift 5-6/2013 Zur Ausgabe

Themenschwerpunkt

Übersicht: Lebertumore